1P-LSD (1-Propionyl-d-lysergic acid diethylamide) is a psychedelic substance similar to LSD (Lysergic acid diethylamide). It is structurally related to LSD and acts as a prodrug, meaning it is converted into LSD in the body¹².

Pharmacology and Effects

1P-LSD is a serotoninergic hallucinogen. It interacts with the central nervous system by activating serotonin receptors, particularly the 5-HT2A receptor, similar to how LSD operates¹².

Subjective and Physiological Effects

1P-LSD can induce a range of effects similar to LSD, including:

• Altered sensory perception and time distortion
• Enhanced introspection and emotional experiences
• Visual hallucinations

On a physiological level, it can cause:

• Increased heart rate and blood pressure
• Elevated body temperature
• Potential for mild adverse effects like headaches, dizziness, and fatigue³.

Safety and Legal Status

1P-LSD's legal status varies by country. It is controlled under analog laws in some regions but remains unscheduled in others. The pharmacokinetics and safety profiles are comparable to those of LSD, with studies indicating that it typically elicits moderate physiological responses at standard doses⁴⁵.

Conclusion

While research on 1P-LSD is still evolving, evidence suggests that it acts similarly to LSD in both effects and risks. However, due to its legal status variability and potential risks, caution is advised for its use and research.

Footnotes

1. Friederike Holze, "Safety pharmacology of acute LSD administration in healthy subjects," PubMed Central, 2021. ↩ ↩²

2. Simon D. Brandt, "Return of the lysergamides. Part I: Analytical and behavioral characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)," PubMed Central, 2024. ↩ ↩²

3. Rie Tanaka, "Identification and Analysis of LSD Derivatives in Illegal Products as Paper Sheet," PubMed, 2021. ↩

4. Adam L. Halberstadt, "Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)," PubMed Central, 2020. ↩

5. Christina Grumann, "Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration," PubMed, 2020. ↩